Bio-Path Holdings Inc (NASDAQ:BPTH) shares gapped up before the market opened on Friday . The stock had previously closed at $12.57, but opened at $18.48. Bio-Path shares last traded at $21.98, with a volume of 4130486 shares.
Separately, ValuEngine lowered shares of Bio-Path from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd.
In related news, major shareholder Armistice Capital Master Fund sold 64,457 shares of the firm’s stock in a transaction that occurred on Friday, January 18th. The shares were sold at an average price of $2.66, for a total value of $171,455.62. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 8.65% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Bio-Path (BPTH) Shares Gap Up to $18.48” was originally posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://dakotafinancialnews.com/2019/03/24/bio-path-bpth-shares-gap-up-to-18-48.html.
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Further Reading: What are catch-up contributions?
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.